KBio aims to create a new generation of biologics using its plant-based platform that has demonstrated the ability to create drug candidates at a fraction of the time and cost of conventional platforms. The Company is focused on developing novel product candidates in two core areas: 1) Antibody therapies for areas of high unmet need; and 2) Pandemic preparedness and response using its plant-based production system to create antibodies and vaccines in shorter timeframes than industry norms.
Formed in December 2021, KBio is a subsidiary of BAT with operations in the UK and U.S.
Company Details
- Employees
- 48
- Address
- Owensboro, Kentucky 42301, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.kbio.com
- HQ
- Owensboro, Kentucky
Kbio Questions
Kbio's website is http://www.kbio.com
Kbio's LinkedIn profile is https://www.linkedin.com/company/kbio
Kbio has
48 employees.
View email and phone details for 48
employees at Kbio.
Kbio's industry is
Biotechnology Research
Kbio's top competitors are
Edera Farm,
Zabbio, Inc.,
Anheart Therapeutics,
Plantform Corporation,
Swiftpharma,
Astrazeneca,
Zero,
Perspective Therapeutics,
Milliporesigma,
Simabs.
Kbio's categories are Biotechnology Research
